If antihistamines are not sufficient and IgE levels are low

Chronic urticaria often leads to a high level of suffering, but new treatment options are on the way – a lot has happened since the publication of the current S3 guideline. Dupilumab is another biologic that has received FDA/EMA approval for CSU, but only for omalizumab-naïve patients. Remibrutinib, a small molecule, has also cleared the approval hurdles in the USA and new data is available on the biologics barzolvolimab and briquilimab. Total IgE is becoming increasingly important as a predictive biomarker for selecting the appropriate first-line systemic therapy.